A modern David versus Goliath story in cancer drug development is unfolding as Clovis Oncology race to market against AstraZeneca; both companies have drugs in early clinical development that appear effective against T790M mutated lung cancer, for which there is currently no approved treatment.
Tag Archives | pharma market analysis
One of the hot topic of conversation amongst the VCs at the JP Morgan Healthcare conference in San Francisco this past week was the field of immuno-oncology. We have already seen significant excitement in anti-PD1/PD-L1 drugs and their early promise in melanoma, renal and lung cancers. Taking a more strategic view, however, the question is how will immuno-oncology change the treatment landscape on a broader scale?
Sally Church, PhD on Pharma Strategy Blog has written about research on macrophage cell surface protein S100A10 and the role this plays in cancer metastasis and tumor growth. As Sally notes, “macrophages are critical in driving tumour growth, invasion and metastasis. Macrophages are like the Pacmen of cells…” What a great visual metaphor! Recently published […]
Last week, Biotech Strategy Blog celebrated one year of publication! Two of the most read posts on Biotech Strategy Blog in its first year were: Lucentis v Avastin CATT trial results in AMD (briefing at ARVO) Prostate Cancer Intervention versus Observation (PIVOT) trial data (presented in plenary session at AUA) You can read more on […]
Earlier this summer, the Food and Drug Administration (FDA) Oncology Drugs Advisory Committee (ODAC) announced a positive decision for Seattle Genetics’ Adcetris™ (brentuximab vedotin) in Hodgkin Lymphoma (HL) and Analplastic Large Cell Lymphoma (ALCL). As Sally Church on Pharma Strategy Blog reported earlier this week, Seattle Genetics has just received fast track approval from the […]
At ASCO this year, there was a lot of interest in BRAF mutated melanoma, with data being presented in the plenary session on vemurafenib (PLX4032) and ipilimumab. However, as Sally Church on Pharma Strategy Blog points out, 40% of all new cancer cases are due to non-melanoma skin cancer, with over one million diagnoses each […]
One of the services that Icarus Consultants offers is to monitor competitor activity in a market, therapeutic area or pathway, and advise clients on new developments. For those interested in metastatic melanoma, this week saw Roche/Genentech make marketing applications to the FDA in the United States and European EMEA for PLX4032 (vemurafenib) in BRAF V600E […]
As marketing strategy consultants we are often called upon to look at the market opportunity in the United states for a company, a new drug or indication. In order to do this it’s necessary to keep on top of the regulatory and reimbursement challenges that pharmaceutical and biotechnology companies face in the U.S. market. Healthcare […]
Mice seem to get bad PR; there’s far more people that like cats……..So in the interests of fair balance, we’d like to draw attention to the increasing importance of preclinical mouse models in cancer drug development. Pieter Droppert on Biotech Strategy Blog discusses how innovations in translational medicine, and improved mouse models of human cancer […]